Drugs / human rotavirus (HRV) vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03954743 | Jul 2019 → Nov 2020 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human rotavirus (HRV) vaccine | “The purpose of this study is to complete the total safety database size for GlaxoSmithKline Biologicals' (GSK's) human rotavirus (HRV) vaccine across the Porcine circovirus...” NCT03954743 ↗ |
| Known as | HRV vaccine | “Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks” NCT03954743 ↗ |
| Modality | Vaccine | “oral live attenuated human rotavirus (HRV) vaccine” NCT03954743 ↗ |
| Route | Oral | “2 doses administered orally at Day 1 and at Month 1 or Month 2” NCT03954743 ↗ |